We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
26
DELISTED
Catalyst Pharmaceutical
CPRX
$7.3M 0.99%
349,649
-68,201
-16% -$1.47M
AVTX icon
27
Avalo Therapeutics
AVTX
$1.01B
$7.21M 0.98%
970,259
-100
-0% -$1.07K
CYTK icon
28
Cytokinetics
CYTK
$10.6B
$7.06M 0.96%
149,982
-20,165
-12% -$1.05M
DYN icon
29
PUT
Dyne Therapeutics
DYN
$4.68B
$6.62M 0.9%
280,800
+147,800
+111% +$4.37M
VIR icon
30
Vir Biotechnology
VIR
$1.46B
$6.59M 0.9%
+897,862
New +$7.08M
TECX
31
Tectonic Therapeutic
TECX
$536M
$6.57M 0.89%
142,328
-124,817
-47% -$5.28M
SYRE icon
32
Spyre Therapeutics
SYRE
$8.5B
$6.57M 0.89%
282,159
-20,088
-7% -$589K
BBIO icon
33
BridgeBio Pharma
BBIO
$16.4B
$5.92M 0.81%
215,713
-69,900
-24% -$1.81M
KOD icon
34
Kodiak Sciences
KOD
$2.5B
$5.73M 0.78%
576,166
+99,580
+21% +$572K
RCUS icon
35
Arcus Biosciences
RCUS
$3.33B
$5.63M 0.77%
378,363
-365,637
-49% -$5.97M
AKRO
36
PUT
DELISTED
Akero Therapeutics
AKRO
$5.54M 0.75%
199,000
+100
+0.1% +$3.03K
ONC
37
CALL
BeOne Medicines Ltd
ONC
$33.9B
$5.5M 0.75%
29,800
– –
DRUG
38
Bright Minds Biosciences
DRUG
$697M
$5.48M 0.75%
+152,211
New +$5.36M
VIR icon
39
CALL
Vir Biotechnology
VIR
$1.46B
$5.29M 0.72%
+720,300
New +$5.68M
CLDX icon
40
PUT
Celldex Therapeutics
CLDX
$2.94B
$5.19M 0.71%
205,500
-100,000
-33% -$2.72M
CAPR icon
41
CALL
Capricor Therapeutics
CAPR
$4.98M 0.68%
361,100
+61,100
+20% +$1.07M
ELDN icon
42
Eledon Pharmaceuticals
ELDN
$255M
$4.64M 0.63%
+1,126,637
New +$4.44M
ACOG
43
Alpha Cognition
ACOG
$192M
$4.45M 0.61%
+755,867
New +$4.24M
SRRK icon
44
CALL
Scholar Rock
SRRK
$5.88B
$4.41M 0.6%
102,100
-100,000
-49% -$3.26M
LENZ
45
LENZ Therapeutics
LENZ
$179M
$4.32M 0.59%
149,502
-55,011
-27% -$1.68M
RZLT icon
46
Rezolute
RZLT
$453M
$4.2M 0.57%
857,230
-30,000
-3% -$151K
MRNA icon
47
PUT
Moderna
MRNA
$21.6B
$4.16M 0.57%
+100,000
New +$4.78M
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.64B
$4.14M 0.56%
34,087
-20,089
-37% -$2.46M
CAPR icon
49
PUT
Capricor Therapeutics
CAPR
$4.14M 0.56%
300,000
– –
EOLS icon
50
Evolus
EOLS
$397M
$4.12M 0.56%
373,265
+114,986
+45% +$1.62M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.